DRL stock falls 10% after missing Q1 estimates, probe by US SEC

Dr Reddy’s Laboratories has reported a consolidated net profit of Rs 570.8 crore in the first quarter of FY22, a 1.5 per cent dip on a year-on-year basis (YoY), while revenue from operations grew by 11.4 per cent to Rs 4,919.4 crore during the quarter.

Dr Reddy’s said it had received a subpoena (written order to attend court to give evidence) from the American market regulator Securities and Exchange Commission (SEC) for producing documents concerning the Commonwealth of Independent States (CIS) geographies.

The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22 and the US market regulator’s subpoena on documents for CIS geographies.


Kunal Randeria of Edelweiss Securities said the disappointing numbers, the big margin miss, and the subpoena by the following an investigation into practices in Ukraine were the reasons behind the stock fall.

“The company has commenced a detailed investigation into an anonymous complaint. The complaint alleges that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of US anti-corruption laws, specifically the US Foreign Corrupt Practices Act. A US law firm is conducting the investigation at the instruction of a committee of the company’s board of directors,” it said in the exchange filing.”The financial performance of the quarter has been driven by healthy sales growth,” said G V Prasad, co-chairman and MD.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Dr Reddy’s

First Published: Wed, July 28 2021. 01:17 IST